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Bcl2 Regulation by the Melanocyte Master
Regulator Mitf Modulates Lineage Survival
and Melanoma Cell Viability
ing and adult mouse. Mitf expression is also clinically
employed in the diagnosis of human melanocytic neo-
plasms, especially melanoma (Chang and Folpe, 2001;
Dorvault et al., 2001; King et al., 1999, 2001; Koch et al.,
2001; Miettinen et al., 2001). Mutations in Mitf produce
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The complete absence of melanocytes in neonatal
Mitf mutant mice could arise either from transdifferentia-
tion during migration of neural crest-derived precursorsSummary
or from loss of survival (or both). Alleles like Mitf vit/vit,
which exhibit essentially normal pigmentation at birthKit/SCF signaling and Mitf-dependent transcription
followed by graying due to melanoycte loss (Lerner etare both essential for melanocyte development and
al., 1986), suggest that Mitf plays an active role in modu-pigmentation. To identify Mitf-dependent Kit tran-
lating postdevelopmental melanocyte survival. How-scriptional targets in primary melanocytes, microarray
ever, transcriptional target genes of Mitf that regulatestudies were undertaken. Among identified targets
melanocyte survival have not yet been elucidated. Thiswas BCL2, whose germline deletion produces melano-
is of particular importance because Mitf could also mod-cyte loss and which exhibited phenotypic synergy with
ulate survival in melanomas, virtually all of which retainMitf in mice. BCL2’s regulation by Mitf was verified in
Mitf expression and exhibit notorious resistance to anti-melanocytes and melanoma cells and by chromatin
neoplastic therapies.immunoprecipitation of the BCL2 promoter. Mitf also
Kit and Scf mutant mice, like Mitf mutants, exhibitregulates BCL2 in osteoclasts, and both Mitf mi/mi and
striking coat color phenotypes due to loss of viableBcl2/ mice exhibit severe osteopetrosis. Disruption
melanocytes (Russell, 1979; Witte, 1990). Although Kitof Mitf in melanocytes or melanoma triggered pro-
activates the PI3-Kinase-Akt survival pathway, geneti-found apoptosis susceptible to rescue by BCL2 over-
cally engineered mouse mutants revealed that this path-
expression. Clinically, primary human melanoma ex-
way was dispensable for melanocyte development,
pression microarrays revealed tight nearest neighbor though it was important for germ cell survival (Blume-
linkage for MITF and BCL2. This linkage helps explain Jensen et al., 2000), suggesting that Kit’s melanocyte
the vital roles of both Mitf and Bcl2 in the melanocyte survival effect is mediated by a different pathway. Kit
lineage and the well-known treatment resistance of may reside upstream of Mitf via at least two potential
melanoma. mechanisms in melanocytes. Kit stimulation triggers
MAPK-mediated phosphorylation of Mitf, which in turn
Introduction recruits the p300 transcriptional coactivator (Hemesath
et al., 1998; Price et al., 1998; Weilbaecher et al., 2001)
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loop-helix leucine zipper (b-HLH-Zip) transcription fac- Moreover, MAPK-dependent Rsk activation may pro-
tor essential for the melanocyte lineage in the develop- duce CREB phosphorylation and upregulation of the
Mitf promoter. The phenotypic overlap of mice harboring
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Ohio 43614. the melanocyte lineage. It is plausible that survival path-
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Figure 1. Microarray Screen for Mitf-Depen-
dent Targets of the SCF Pathway
(A) Treatment with either SCF or TPA leads to
a phosphorylation-induced Mitf mobility shift.
Primary human melanocytes were stimulated
with either stem cell factor (SCF) or TPA for
indicated times and harvested for Western
blot analysis using monoclonal Mitf. Faint
upper bands (labeled with asterisks) repre-
sent alternate forms of Mitf transcribed from
separate promoters.
(B) Expression of adenovirus-encoded pro-
teins in primary human melanocytes infected
for 48 hr with control (GFP), wild-type (wt), or
dominant-negative (DN) Mitf viruses.
(C) Disruption of endogenous Mitf:DNA com-
plexes by dnMitf adenovirus. Nuclear extracts
from control (GFP) or dnMitf (DN)-infected
primary human melanocytes at different mul-
tiplicities of infection (MOI) were incubated
with a 32P-labeled Mitf DNA probe and super-
shifted with a monoclonal antibody against
Mitf.
(D) Summary of screen results from expres-
sion profiling of melanocytes stimulated by
SCF or TPA  cycloheximide (CHX) and 
dnMitf (see Experimental Procedures).
ways may operate in melanocytes, which are unique substitute for SCF in these cultures (data not shown).
TPA stimulation produces the identical MAPK-mediatedfor the requirement to survive UV exposure to ensure
Mitf phosphorylation as for SCF in both primary melano-melanin synthesis. The notorious treatment resistance
cytes and melanoma cells (Figure 1A; Hemesath et al.,of melanoma suggests that melanocyte-specific survival
1998; Wu et al., 2000). We chose to identify target genespathway(s) might thus operate in a clinically relevant
of SCF/Kit as well as TPA, whose upregulation is depen-fashion.
dent upon the presence of endogenous Mitf. Depen-Here, a microarray-based screen was undertaken to
dence on Mitf was revealed by analyzing expressionidentify Mitf-dependent SCF/Kit target genes in primary
data from stimulated melanocytes that were previouslyhuman melanocytes. Among the collection of identified
infected by adenoviruses expressing a specific domi-targets was BCL2, the antiapoptotic factor (Gross et al.,
nant-negative Mitf mutant (or control GFP virus). The1999; Reed, 1998; Vander Heiden and Thompson, 1999)
dominant-negative Mitf mutation contains a basic do-whose germline deletion results in early loss of the mela-
main amino acid deletion and thereby sequesters wild-nocyte lineage. Mitf and Bcl2 were found to genetically
type Mitf partners, but not other HLH proteins, into di-interact in vivo as demonstrated by profound melano-
mers incapable of binding DNA (Hemesath et al., 1994).cyte loss in compound heterozygous mice. In addition,
Because adenoviruses disrupted SCF signaling events,we show that Mitf occupies the BCL2 promoter, regu-
we employed TPA stimulation, which was not measur-lates endogenous levels of BCL2 in melanocytes and
ably affected by viral infection (data not shown). Themelanomas, and is coregulated with BCL2 in primary
adenovirus vectors infected 98% of cultured primaryhuman melanoma samples analyzed in microarray near-
melanocytes or melanoma cells (data not shown) andest neighbor analyses. Finally, modulation of BCL2 ex-
measurably expressed the encoded proteins (Figurepression is shown to be critical for melanocyte and mela-
1B). Dominant-negative Mitf adenovirus producednoma survival.
dose-dependent inhibition of DNA binding by endoge-
nous Mitf (revealed as monoclonal antibody-induced su-
Results pershift) in nuclear extracts of infected melanocytes
(Figure 1C). Using this system, expression profiling was
Microarray Screen for SCF/Kit/Mitf Target Genes undertaken.
To identify SCF/Kit transcriptional targets, primary hu- Target genes in primary, early passage human mela-
man melanocytes were stimulated with recombinant nocytes were identified for SCF, TPA, the overlap of
SCF, and a time course of mRNAs was isolated up to SCF and TPA, and the subgroups of SCF/TPA targets
6 hr later. Kit stimulation produces a well-characterized whose activation is dependent or independent of Mitf,
MAP kinase-mediated phosphorylation of Mitf, which is as well as those whose induction by SCF or TPA is
manifested as a protein mobility shift by Western blot sensitive versus resistant to cycloheximide (raw data are
(Figure 1A; Hemesath et al., 1998). TPA is a commonly available as Supplemental Data at http://www.cell.com/
employed growth factor for primary melanocytes (Ei- cgi/content/full/109/6/707/DC1). As summarized in Fig-
ure 1D, a total of 204 genes were upregulated at multiplesinger and Marko, 1982; Halaban et al., 1986) and may
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time points by SCF/TPA (2-fold), with 128 displaying (Figure 2C). Early-onset graying was also observed in
Mitf vit/vit;Bcl2/ mice (Figure 2D).independence of Mitf (resistance to overexpression of
dnMitf) and 76 displaying Mitf dependence (induction To assess whether coat color whitening resulted from
melanocyte loss (versus depigmentation of viable mela-that was lost in the presence of dnMitf). Of the Mitf-
independent targets, 20 were sensitive to cycloheximide nocytes), a Dct-LacZ transgene that tags the melano-
cyte lineage (Mackenzie et al., 1997) was employed. Intreatment (likely indirect targets of SCF/TPA), while 108
were resistant to cycloheximide. Of the Mitf-dependent unpigmented hair follicles of mice triply heterozygous
for Mitf vit, Bcl2, and the Dct-LacZ transgene, a strikingtargets, 40 were sensitive to cycloheximide, and 36 were
resistant. lack of LacZ-positive cells (melanocytes) was seen, rela-
tive to age-matched littermate controls (Figure 2E). HairA group of SCF/TPA targets that internally validates
the experiment contains the immediate-early genes follicles from regions that had not yet depigmented did
contain LacZ-positive melanocytes (data not shown),JUN, FOS, EGR1, and MYC. These genes were all signifi-
cantly induced, and their induction was cycloheximide demonstrating that depigmentation in these mice is as-
sociated with loss of viable melanocytes. These obser-resistant, as anticipated for immediate-early genes. Fur-
thermore, whereas induction of MYC and EGR1 was vations demonstrate genetic cooperativity between Mitf
and Bcl2 for melanocytes.unaffected by dnMitf, both JUN and FOS induction were
blocked by dnMitf, suggesting a connection (either di-
rect or indirect) between Mitf activity and the signaling Mitf Binding and Regulation of the BCL2 Promoter
pathway through which these factors are induced down- We next examined the BCL2 promoter for potential Mitf
stream of Kit and TPA in melanocytes. Importantly, the binding sites that fit the E box consensus sequence
resistance of MYC (as well as the vast majority of genes CA[C/T]GTG and identified a CATGTG element 220 base
on the microarray) to dnMitf helps to validate a specific pairs upstream of the transcriptional start (Figure 3A).
role of Mitf for the genes whose expression is modulated Chromatin immunoprecipitation revealed that this E
by dnMitf, though the directness of the relationships box-containing region of the BCL2 promoter was ampli-
cannot be assessed from these data alone. Ultimately, fied from crosslinked chromatin isolated from 501mel
independent verification of target gene relationships is human melanoma cells and immunoprecipitated with
important (as shown for BCL2 below); however, to qual- anti-Mitf antibody but not from multiple controls, includ-
ify as a target, a gene must be upregulated indepen- ing an unrelated antibody, the same anti-Mitf antibody
dently by both SCF and TPA (in separate experiments) tested for binding to the 3 untranslated region of the
and then at multiple time points. BCL2 gene, or no template control (Figure 3B). In addi-
Table 1 shows selected sets of Mitf-dependent and tion, the specificity of this interaction was observed un-
-independent SCF/TPA target genes identified by this der more stringent immunoprecipitation wash condi-
screen. Among the potential targets (further analysis will tions containing lithium chloride (lanes 4 and 6). EMSA
be presented elsewhere, M.H. and D.E.F., unpublished was also performed, using the E box-containing pro-
data) the antiapoptotic factor Bcl2 was noteworthy be- moter region as probe and 501mel human melanoma
cause Bcl2 homozygous knockout mice (Veis et al., nuclear extract as a source of MITF protein, together
1993) exhibit dramatic depigmentation due to loss of with MITF monoclonal antibody for supershift. We ob-
melanocytes shortly after birth (Kamada et al., 1995; served an MITF-specific supershifted complex (Figure
Yamamura et al., 1996). Therefore, a possible relation- 3C) and confirmed sequence specificity of this complex
ship between Mitf and Bcl2 was further investigated. by cold competition assays in which wild-type probe
competed the supershift, whereas a double-point mu-
tant probe did not. These results indicate that MITFMitf and Bcl2 Interact Genetically In Vivo
directly occupies the BCL2 promoter in vivo and suggestTo examine genetic interactions between Mitf and Bcl2
that BCL2 may be a direct transcriptional target of MITF.in vivo, we generated compound heterozygote crosses
To confirm and extend the microarray observationfor a Bcl2 null allele (which is recessive) as well as the
that MITF regulates endogenous BCL2 gene expression,vitiligo mutation of Mitf, Mitf vit (which is also recessive).
primary human melanocytes and human melanoma cellsThe Mitf vit mutation weakly diminishes the DNA binding
were infected with adenoviruses expressing either nu-affinity of Mitf (Steingrimsson et al., 1994; Hemesath et
clear-targeted GFP (control), wild-type MITF, or domi-al., 1994). Mitf vit/vit mice are born black with occasional
nant-negative MITF. In melanocytes, wild-type MITF sig-white spots and display postnatal melanocyte loss,
nificantly upregulated BCL2 mRNA relative to dnMITFwhereas Mitf vit/ (heterozygous) mice are black and
by quantitative RT-PCR (Figure 4A). Correspondingly, inshow no melanocyte loss over time. Similarly, mice ho-
501mel human melanoma, wild-type MITF induced andmozygous for the targeted mutation Bcl2tm1Sjk (hereafter
dnMITF significantly reduced endogenous BCL2 relativeBcl2/) display profound melanocyte loss shortly after
to controls (Figures 4B and 4C). Finally, transient trans-birth, whereas Bcl2/ (heterozygous) mice are fully pig-
fections revealed that the wild-type BCL2 promoter wasmented and display no age-dependent changes (Ka-
upregulated by MITF in a manner that was lost uponmada et al., 1995; Yamamura et al., 1996).
mutating the E box (Figure 4D).Mitf vit/, Bcl2/ compound heterozygotes displayed
a striking pattern of melanocyte loss over time (Figure
2). Melanocyte loss began shortly after birth ventrally Mitf Regulates Bcl2 Levels in Osteoclasts
In addition to loss of viable melanocytes, a number ofand was accompanied by slower generalized graying
throughout (Figures 2A and 2B). Compound heterozy- strong alleles of Mitf display defects in osteoclasts that
manifest as osteopetrosis, a condition of shortened stat-gotes also displayed white snout whiskers by 8 weeks
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Table 1. SCF/TPA Target Genes
Select Cycloheximide-Resistant Targets
Mitf Dependent Mitf Independent
Acc. Number Gene (Fold) Acc. Number Gene (Fold)
D90209 ATF4 (CREB2) 10 M65214 TCF3 2
M25269 ELK1 5.7 X96381 Erm 4.8
U85658 Transcription factor ERF-1 3.5 L19067 P65 (NF kappa B subunit) 2.2
U69126 FUSE binding protein 2 (FBP2) 4.1 M29551 PP2B 3.1
U28049 TBX2 3.5 L40027 GSK-3 2.4
U48807 Dual specific protein phosphatase 8.3 X59932 CSK 2.5
L04733 KINESIN LIGHT CHAIN 4 V00574 c-Ha-ras1 2.1
X91247 TXNRD1 Thioredoxin reductase 3.1 X98001 Geranylgeranyl transferase II 2.3
X51345 JUNB 27 J03805 Phosphatase 2A 2.9
V01512 c-fos 34 U19796 Melanoma antigen p15 2.6
X55504 Proliferating Cell Nucleolar Antigen 4.1 U91930 AP-3 complex delta subunit 2.9
(HG1116-HT1116) X06985 HMOX1 Heme oxygenase 1 3.2
AB000584 Prostate differentiation factor mRNA 11 X99720 TPRC gene 2
X76771 Rad2 (HG4074-HT4344) 4.1 J04444 CYC1 Cytochrome c-1 2.4
X93499 RAB7 2.2 X66945 FGFR1 6
X57522 TAP1 Transporter 1, ABC 3.1 L08246 MCL1 4.5
J03161 SRF 2.4
M14745 BCL-2 2.5 L76191 IL-1 receptor-associated kinase 2.7
X56681 JunD 2.8
S81914 IEX-1 55
X52541 EGR1 29
X59798 CCND1 Cyclin D1 10
M13930 C-Myc, Alt. Splice 3 (HG3523-HT4899) 2.5
M58286 TNFR1 12.1
L07395 PP1, Alpha Catalytic Subunit (HG1614-HT1614) 2
X06614 Receptor of retinoic acid 10.8
D78577 YWHAH 3.4
M13194 ERCC1 3.4
Select Cycloheximide-Sensitive Targets
Mitf Dependent Mitf Independent
Acc. Number Gene (Fold) Acc. Number Gene (Fold)
S87759 PP2C alpha 2.1 L20298 CBFB 2.1
L38810 TRIP1 2.4 M95929 PHOX1 2.2
M12128 Tropomyosin Tm30nm (HG3514-HT3708) 2.2 U29680 Bfl-1 2.6
L11066 Mitochondrial Stress-70 Protein 2.2 U84388 CRADD 2.7
Z49099 Spermine synthase 3.2 D17547 TRP 2/DCT 2.6
J03407 Ret finger protein (HG2825-HT2949) 2.2 U18934 TYRO3 3.2
Z24725 mig-2 4.1 U21090 DNA polymerase delta small subunit 3.4
D14878 Protein D123 2.8
U14603 PTPCAAX2 2.9
U50523 BRCA2 region, sequence CG037 2.2
Selected genes from each category shown in Figure 1D (raw data available as Supplemental Data at http://www.cell.com/cgi/content/full/
109/6/707/DC1.
ure due to hyperdense bones with partial ablation of the ble in both osteoclast types (data not shown). Moreover,
levels of Bad, a proapoptotic member of the Bcl2 family,marrow cavity (Moore, 1995; Weilbaecher et al., 1998).
Osteopetrosis in Mitf mutants is associated with dimin- and -tubulin were comparable. In addition, using the
same adenoviral infection system, we observed that Mitfished numbers of fully developed, multinucleated osteo-
clasts. Whereas melanocytes are entirely absent in regulates endogenous BCL2 mRNA levels in primary
human osteoclasts (Figure 5B). This response was spe-Mitfmi/mi mutant mice, osteoclasts can be isolated from
these mice (likely due to partial compensation by the cific to BCL2 since levels of GAPDH and the osteoclast
receptor FMS (data not shown) were unchanged.Mitf family member TFE3), and these osteoclasts permit
analysis of whether Bcl2 expression is diminished in the Since Mitf mi/mi mice display severe osteopetrosis, we
examined the possibility that loss of Bcl2, as a target ofsetting of Mitf deficiency.
Bcl2 protein in Mitf mi/mi osteoclasts is greatly reduced Mitf, might similarly produce osteopetrosis, a phenotype
potentially consistent with the short stature and “hunch-in comparison to wild-type littermate controls (Figure
5A). This decrease is not due to an overall defect or back” appearance originally described for these mice
(Kamada et al., 1995; Nakayama et al., 1994; Veis et al.,reduction in cell number, because expression of the
osteoclast marker genes RANK and Fms were compara- 1993). Bone densities of Bcl2/ mice and wild-type
MITF Regulates Bcl2 in Melanocytes and Melanoma
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Figure 3. Mitf Binds the BCL2 Promoter
(A) Diagram of the human BCL2 gene promoter region showing
Figure 2. Mitf and Bcl2 Genetically Interact In Vivo putative Mitf binding site (filled gray box).
Mitf-vitiligo and Bcl2 double heterozygotes (n  49) exhibit dorsal (B) Chromatin immunoprecipitations were performed from log-
(A) and ventral (B) depigmentation compared to Mitf-vitiligo hetero- phase 501mel human melanoma cells. No DNA (lane 8); protein:chro-
zygous control littermates (n  63). matin-crosslinked complexes immunoprecipitated with either con-
(C) Whisker depigmentation was seen within 8 weeks in compound trol antibody (lanes 3 and 4), Mitf antibody (lanes 5 and 6), or no
heterozygotes. antibody (lane 2); and input genomic DNA (lane 7) were run with
(D) Mitf vit/vit /Bcl2/ animals (n  29) also exhibited depigmentation DNA markers (M, lanes 1 and 9) and stained with EtBr. PCR primers
relative to Mitf-vitiligo littermate controls (n  11). spanning either promoter or 3UTR (control) regions were employed.
(E) X-Gal staining of skin sections prepared from the whisker region (C) EMSA was performed on the putative Mitf binding site shown
of 8-week-old Dct-lacZ transgenic mice either heterozygous for Mitf- in (A) using 501mel nuclear extract with 32P-labeled DNA probe. Mitf
vitiligo (left) or compound heterozygous for Mitf-vitiligo and Bcl2 bound complexes were identified by supershift, and cold competi-
(right). Hair follicles (indicated by arrow heads) contain LacZ cells tion was performed in 5- or 25-fold excess unlabeled wild-type or
(melanocytes) in Mitf-vitiligo heterozygotes (controls), but not in mutant DNA probes. Asterisks show non-Mitf-containing com-
compound Mitf-vitiligo/;Bcl2/ heterozygotes. plexes.
observations suggest that, in addition to other organlittermate controls were inspected radiographically as
well as histologically. Significantly increased bone den- systems affected, Bcl2/ mice also display significant
bone resorption defects similar to those seen in Mitf mi/misity was observed in the femurs of 2-week-old Bcl2/
mice (Figure 5C). Histologically, osteopetrosis was mice.
prominent in the metaphysis of long bones (Figure 5C),
where considerable chondro-osseous trabeculae (pri- Mitf Is Critical for Melanocyte and Melanoma
Cell Survivalmary spongiosa) accumulated with extensive thickening
compared to age-matched wild-type littermates. Mar- If modulation of BCL2 expression by Mitf were function-
ally relevant for melanocyte or melanoma cell viability,row spaces were diminished in size, and the cortical
plate of the long bones was thicker than normal. These then interference with Mitf activity may affect survival in
Cell
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Figure 4. Mitf Regulates Endogenous BCL2
in Melanocytes and Melanoma
Quantitative RT-PCR analysis of BCL2 RNA
from (A) primary human melanocytes infected
with either Mitf wild-type (wt) or dominant-
negative (DN) adenovirus (MOI: 200) after 72
hr, (B) 501mel human melanoma infected with
either control (Ctrl) or Mitf wild-type (wt) ade-
novirus (MOI: 200) after 48 hr, or (C) 501mel
cells infected with control (Ctrl) or Mitf domi-
nant-negative (DN) adenovirus (MOI: 500)
after 72 hr. BCL2 levels were normalized to
GAPDH and performed in triplicate.
(D) Luciferase reporter assays demonstrate E
box-dependent responsiveness of the human
BCL2 reporter to Mitf.
these cells. To address this question, we asked whether ular lymphoma. Expression profiles of patient-derived
primary human melanomas were examined for MITF anddominant-negative Mitf impacts on viability of primary
melanocytes and melanoma cells. Using the same ade- BCL2 levels. As shown in Figure 6D, a very tight correla-
tion was seen in their expression patterns. Among thesenovirus system described above, we observed that
dominant-negative Mitf produced a significant increase tumors, several display relatively low MITF expression,
yet MITF expression even in these samples is signifi-in primary melanocyte death in culture over wild-type
infected cells (Figure 6A). A similar pattern of cell death cantly higher than in most nonmelanomas examined in
identical microarray analyses (data not shown). Thus,occurred in human melanoma cells. The effects of dnMitf
were compared to a different mutant of Mitf defective expression of MITF and BCL2 is tightly correlated in
human melanomas.in dimerization and functionally null (Hemesath et al.,
1994). dnMitf, but not the recessive allele, produced
substantial apoptosis in human melanoma cells (Figure Discussion
6B). To determine whether BCL2 overexpression from
a constitutive promoter could rescue dnMitf-induced Microarray Screen for Stem Cell Factor/Kit
Target Genesapoptosis in melanoma cells, we quantitated the sub-
diploid (apoptotic) population in melanoma cells that The present study provides a systematic array-based
approach to the identification of SCF/Kit-induced tran-stably overexpress BCL2 off the LTR of pBABE-BCL2-
puro. Moreover, cell death induced by dnMitf was signifi- scriptional targets in the melanocytic lineage. SCF sig-
naling has a substantial impact on the transcriptionalcantly rescued by constitutive BCL2 overexpression
(Figure 6C). Of note, although BCL2 measurably rescued repertoire of primary melanocytes, affecting diverse tar-
get gene functional categories such as survival, prolifer-apoptosis in the presence of dnMitf, it could not rescue
colony formation in separate experiments (data not ation, signaling, redox, DNA repair, motility, membrane
trafficking, and other aspects of melanocytic differentia-shown), consistent with the possibility that Mitf regu-
lates additional target genes that are essential to prolif- tion. Genes that had been previously implicated as SCF/
Kit-responsive in other cell types (such as FOS, JUNB,eration or survival. The identification of BCL2 as an Mitf
target, but not the only important target, is also consis- EGR1, and MYC genes in hematopoietic cells) were con-
firmed as Kit targets in primary melanocytes. This list alsotent with the observation that Bcl2 null mice lose pig-
mentation after birth, whereas Mitf null mice are devoid includes BCL2, now shown to specifically involve Mitf.
Human natural killer cells have been shown to expressof melanocytes already at birth.
If the Mitf:BCL2 relationship were maintained in mela- BCL2 in response to SCF as a survival mechanism (Car-
son et al., 1994). This pathway may similarly involve Mitfnomas, then their expression patterns in patient samples
should correlate. Alternatively, BCL2 expression might because NK cell defects have previously been described
in Mitf-deficient mice (Ito et al., 2001). In addition, sur-be disconnected from its regulators, as in t14;18 of follic-
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Figure 5. Mitf Regulates Bcl2 Levels in Os-
teoclasts
(A) Lysates were prepared from primary mu-
rine osteoclasts isolated from the spleen of
either Mitf wild-type (wt) or mutant (mut) mice
and blotted for Bcl2, Bad, or tubulin.
(B) Northern blot analysis of primary human
osteoclasts infected with Mitf wild-type (wt),
control (Ctrl), or dnMitf (mut) adenovirus.
(C) Bone changes in 2-week-old Bcl2/ or
wild-type (wt) mice was assessed by X-ray
and histochemistry (H&E, 4	 magnification)
and revealed expanded 1
 spongiosa in
Bcl2/ mice, consistent with osteopetrosis.
vival of mast cells, another of the few Mitf-expressing microarray screen did not extend to time points beyond
6 hr and consisted of only a single cytokine stimulationlineages, appears to be modulated by Kit-induced Bcl2
upregulation (Bullock and Johnson, 1996; Mekori et al., event. Therefore, it may be premature to conclude that
pigment enzyme genes are not targeted by SCF/Kit (or2001).
A number of genes that are thought to be posttransla- by Mitf). The unexpected Mitf dependence of FOS and
JUNB induction occurs through an unclear mechanismtionally modified by SCF/Kit signaling were found to be
transcriptionally regulated as well, potentially consistent that may be indirect. The T box binding protein Tbx2
was also identified in this screen and was previouslywith a feedback pathway that might replenish signaling
intermediates whose activation also targets them for described as an Mitf target gene in melanocytes (Car-
reira et al., 2000). While a more detailed discussion ofdegradation. Among these are Cdkn1a(p21), Hras1,
Raf1, Src, Elk1, and other members of the Ets family. these data is beyond the scope of this report, the com-
plete data set is available online and will be further ana-Based on our data, Dct/Trp2 appears to be regulated by
Kit signaling, independently of Mitf, a finding consistent lyzed separately (M.H. and D.E.F., unpublished data).
Kit’s survival function in melanocytes appears to bewith maintenance of Dct/Trp2 expression in the eyes
(RPE) of Mitf mi/mi mutant mice (Nakayama et al., 1998). independent of the PI3K/Akt pathway (Blume-Jensen et
al., 2000), a finding consistent with the unique require-It is interesting that more pigment genes did not appear
as Kit targets, since it has been shown that chronic ment for Mitf and Bcl2 in this lineage. Kit potently acti-
vates MAPK, which may upregulate Mitf by two mecha-subcutaneous administration of recombinant SCF to hu-
mans results in hyperpigmented melanocytes (Costa et nisms: (1) direct Mitf phosphorylation and recruitment
of p300/CBP (Hemesath et al., 1998; Price et al., 1998),al., 1996). It is important to consider that the current
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Figure 6. Mitf and Bcl2 Are Critical for Mela-
nocyte and Melanoma Survival
(A) Primary human melanocytes were in-
fected (M.O.I of 1000) with Mitf wild-type (wt)
or dnMitf (DN) adenovirus and harvested 48
hr later. Cell death was measured by trypan
blue in triplicate.
(B) FACS analysis of 501mel human mela-
noma cells transfected with E-GFP and either
Mitf wild-type (wt), Mitf dominant-negative
(DN), or Mitf-cloudy eyes null mutant (null).
Fixed and propidium iodine-stained cells
were gated for GFP expression and sub-G1
DNA content quantitated to assess percent
apoptosis.
(C) Enforced BCL2 overexpression rescues
501mel human melanoma apoptosis induced
by dnMitf. Puromycin-selected, pooled pop-
ulations of 501mel cells stably overexpress-
ing either vector control (Vec) or Bcl2 were
transfected with E-GFP and Mitf dominant-
negative. Percent apoptosis in GFP-gated
cells was measured as in (B).
(D) Nearest-neighbor analysis of MITF
(squares) and BCL2 (lozenges) mRNA levels
performed on a series of primary human mel-
anomas analyzed by Affymetrix GeneChip mi-
croarray.
and (2) CREB-mediated increased Mitf expression. The measurable role for Bcl2 in melanoblasts during neural
crest migration. Notwithstanding their black coat colorobservation that interference with Mitf ablates Kit-
induced Bcl2 expression (Figure 1) is thus consistent at birth, Bcl2 homozygous null mice might harbor dimin-
ished numbers of cutaneous melanocytes, whose fur-with the possibility that Mitf is a central effector of this
pathway. ther loss postnatally becomes phenotypically evident
only following subsequent hair follicle cycles.
Genetic Interaction between Mitf and Bcl2
It is noteworthy that homozygous Bcl2 deficiency pro- BCL2 Is a Direct Target of Mitf
Chromatin IP revealed that Mitf protein occupies theduces more gradual melanocyte loss (Kamada et al.,
1995; Veis et al., 1993; Yamamura et al., 1996) than endogenous BCL2 promoter in melanoma cells. This
interaction was specific both for the antibody used andcomplete absence of functional Mitf, Kit, or Scf, which
produce mice devoid of melanocytes from birth. Bcl2 for the BCL2 promoter position and Mitf protein in mela-
noma nuclear extract specifically bound to the E boxmay not play a critical role in melanocyte survival early
in development, or this role may be redundant with other element in the BCL2 promoter in EMSA. Combined with
data showing that up- or downregulation of Mitf modu-family members or survival pathways. It is also possible
that Mitf regulates other essential targets, such as cell lates endogenous BCL2 expression in melanocytes,
melanoma cells, and osteoclasts, these studies suggestcycle components, and that Kit signaling activates addi-
tional survival pathways to account for the delayed phe- that BCL2 is a direct transcriptional target of Mitf. Other
pathways are known to result in BCL2 upregulation innotype of Bcl2 deficiency. In support of this, we have
been unable to rescue pigment cells from Kit deficiency a variety of contexts. These include CREB-mediated
stimulation of the BCL2 promoter, which regulates cer-by transgenic expression of Bcl2 in melanoblasts and
melanocytes (S.A.J. and I.J.J., unpublished). In the con- tain examples of neuronal signal-dependent survival
(Pugazhenthi et al., 1999, 2000). This pathway might betext of Mitfvit/ heterozygotes, additional loss of a single
Bcl2 allele produced depigmentation, which always initi- utilized as well in melanocytes or melanoma cells and
could operate either through direct effects of CREB onated on the belly. Ventral spotting is usually a manifesta-
tion of a neural crest migration defect, suggesting a BCL2 expression or the known role of CREB in upregu-
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lating Mitf expression (Bertolotto et al., 1998; Price et evidence that Mitf is a central transcriptional regulator
of pigmentation (Goding, 2000), it is plausible that Mitfal., 1998). These data are also consistent with the obser-
vation that CREB acts as a survival factor in human links Bcl2 expression to the pigmentation response.
Bcl2’s protective effect may also be directed againstmelanoma cells (Jean et al., 1998).
the chemical stress associated with pigmentation itself,
a possibility which may help explain Bcl2/ melanoblastOsteopetrosis in Bcl2-Deficient Mice
loss during neural crest migration. Unfortunately, one ofModulation of Bcl2 levels by Mitf in primary osteoclasts
the deleterious consequences of this Mitf-Bcl2 linkage isas well as Bcl2 deficiency within Mitfmi/mi osteoclasts
likely to be the extreme treatment resistance of mela-suggest that Mitf regulates Bcl2 in these cells, a finding
noma in humans.also consistent with the osteopetrosis discovered in
Bcl2/ mice, though additional cell:cell signaling could
Experimental Proceduresalso contribute to the phenotype. Additionally, Mitfmi/,
Bcl2/ compound hets exhibited gross craniofacial and
Cell Cultureskeletal abnormalities (data not shown). Recent studies
Primary human melanocytes between passages 2 and 5 from neotal
have demonstrated that M-CSF, the cytokine deficient foreskins (provided by Dr. Ruth Halaban, Yale University) were grown
in Csf1op/op osteopetrotic mice, resides upstream of Mitf in TICVA medium containing Ham’s F10 (GIBCO-BRL), 7% FBS,
within osteoclasts in a manner similar to SCF/Kit in mela- penicillin/streptomycin/glutamine (GIBCO-BRL), 1 	 104 M IBMX
(Sigma), 50 ng ml1 TPA (Sigma), 1 M Na3VO4, and 1 	 103 Mnocytes (Weilbaecher et al., 2001). Prior studies by
dbcAMP (Sigma). Purity of cultures was 95%–99% based upon im-Weissman and colleagues demonstrated partial rescue
munofluorescent staining for the D5 melanocytic marker. For mi-of the Csf1op/op osteoclast lineage by targeted Bcl2 over-
croarrays, primary melanocytes were stimulated with 20 ng ml1
expression (Lagasse and Weissman, 1997). In those human SCF (R&D Systems) or 10 ng ml1 TPA with or without 20
studies, targeted Bcl2 expression may have coinciden- g ml1 cycloheximide for indicated times after an overnight starva-
tally replaced a specific Bcl2 deficiency, rather than tion in F10 medium supplemented only with penicillin/streptomycin/
glutamine. 501mel human melanoma cells (gift of Dr. Halaban, Yaleproviding purely generic survival signals.
Univ.) and osteoclasts were cultured as described (Motyckova et
al., 2001; Wu et al., 2000).Mitf as a Survival Factor in Melanocytes
and Melanoma
Adenoviral InfectionsA number of additional observations appear to link MITF
Adenoviruses were previously described (Motyckova et al., 2001)
and BCL2 within human melanoma. For example, MITF and overexpress either wild-type human Mitf, R215del (dnMitf) or a
and BCL2 levels are maintained in most melanomas GFP/wee1-truncation hybrid (which targets GFP to the nucleus as
vector control) under control of the EF-1 promoter. Subconfluentdespite the common loss of many melanocytic markers,
primary human melanocytes and 501mel human melanoma cellssuch as melanin and Kit. A number of studies have
were incubated with concentrated adenoviruses in serum-free F10reported that BCL2 is widely expressed in human mela-
supplemented with 10 mM MgCl2 for 30 min at a multiplicity ofnoma (Cerroni et al., 1995; Ramsay et al., 1995; Selzer
infection of 200 and 500, respectively. After infection the medium
et al., 1998) without known BCL2 translocations or am- was replaced by fresh, fully supplemented growth medium and cul-
plification, implying a role for this antiapoptotic protein tured for indicated times until stimulation or harvest.
in these notoriously treatment-resistant tumors (Grover
and Wilson, 1996; Selzer et al., 1998). These observa- High-Density Oligonucleotide Array-Based
Expression Profilingtions have prompted clinical trials using BCL2 antisense
RNA was extracted at 0, 0.5, 1, 2, 4, and 6 hr after SCF or TPAoligonucleotides (Banerjee, 2001; Jansen et al., 2000),
treatment of primary human melanocytes. SCF stimulation was car-and particular efficacy in melanoma has prompted ad-
ried out in the absence of adenovirus, while TPA stimulation oc-vancement to phase III trials.
curred 64 hr after infection with control or dnMITF adenoviruses.
In this study we confirm and extend these observa- RNA was prepared and hybridized as described (Coller et al., 2000;
tions by demonstrating that MITF and BCL2 are tightly Lockhart et al., 1996). Each RNA sample was hybridized to a single
high-density oligonucleotide array (HU_6800, Affymetrix) that en-correlated in a nearest neighbor analysis performed on
abled interrogation of the expression levels of 6800 human genesprimary human melanoma expression microarrays. It is
and ESTs. With slight modifications, expression data were analyzedpossible that one of Mitf’s critical roles in melanoma
as previously described (Tamayo et al., 1999). Overall intensity forcould be to regulate BCL2 expression, thereby enhanc-
each chip was equivalent by scaling of intensity values. Fluores-
ing survival. If this were the case, disruption of the Mitf- cence intensities were detected with a laser confocal scanner (Hew-
BCL2 pathway provides a potential tissue-restricted lett-Packard) and processed with Genechip software (Affymetrix).
Small and negative values were thresholded to 100 units. Raw ex-means of targeting melanoma antineoplastic therapy.
pression values were normalized within an experiment to a meanHomozygous Bcl2 deficiency produces a variety of
of zero and a standard deviation of 1.tissue-restricted phenotypes. One potentially interest-
Significant induction of transcription was defined as: (1) an in-ing similarity between lymphocytes and melanocytes
crease of2-fold relative to the 0 hr baseline; (2) for genes exhibiting
that correlates with their shared dependence on Bcl2 a trough pattern of gene expression after SCF, induction criteria
is their unique exposure to DNA damage/translocation were2-fold relative to the time point with lowest expression prior to
the induction during the time course (with at least 1.5-fold inductionintermediates. The importance of Bcl2 in lymphocyte
relative to the 0 hr baseline); (3) induction was present in two orsurvival may relate to the activation of apoptosis by
more time points following stimulation; (4) a target gene was consid-recombination intermediates, a response that may simi-
ered Mitf-dependent if the ratio of its maximum induction in thelarly occur in melanocytes following UV-induced DNA
presence of control virus to the maximum induction in the presence
damage. Just as lymphocytes must survive genomic of dnMitf was 2; (5) a target gene was considered cycloheximide-
recombinations to produce immune responses, melano- sensitive if the ratio of its maximal signal in the absence of cyclohexi-
mide relative to the presence of cycloheximide was 2.cytes must survive UV to produce melanin. Given the
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